Evidence map›Paper›PMID 33482807›Full record

ArticleBMC health services research2021

Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa.

S M Cleary, T Wilkinson, C R Tamandjou Tchuem, S Docrat, G C Solanki

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021
    Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Evidence of quality of life for hospitalised patients with COVID-19: a scoping review.Health technology assessment (Winchester, England) · 2024
    Article
  11. Article
  12. Cost of illness studies in COVID-19: a scoping review.Cost effectiveness and resource allocation : C/E · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S M ClearyHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. susan.cleary@uct.ac.za.
T WilkinsonHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
C R Tamandjou TchuemHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
S DocratHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
G C SolankiHealth Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZASouth African Medical Research Council · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven projected shortages of critical care capacity in public hospitals during the COVID-19 pandemic, the South African government embarked on an initiative to purchase this capacity from private hospitals. In order to inform purchasing decisions, we assessed the cost-effectiveness of intensive care management for admitted COVID-19 patients across the public and private health systems in South Africa.

methodsUsing a modelling framework and health system perspective, costs and health outcomes of inpatient management of severe and critical COVID-19 patients in (1) general ward and intensive care (GW + ICU) versus (2) general ward only (GW) were assessed. Disability adjusted life years (DALYs) were evaluated and the cost per admission in public and private sectors was determined. The model made use of four variables: mortality rates, utilisation of inpatient days for each management approach, disability weights associated with severity of disease, and the unit cost per general ward day and per ICU day in public and private hospitals. Unit costs were multiplied by utilisation estimates to determine the cost per admission. DALYs were calculated as the sum of years of life lost (YLL) and years lived with disability (YLD). An incremental cost-effectiveness ratio (ICER) - representing difference in costs and health outcomes of the two management strategies - was compared to a cost-effectiveness threshold to determine the value for money of expansion in ICU services during COVID-19 surges.

resultsA cost per admission of ZAR 75,127 was estimated for inpatient management of severe and critical COVID-19 patients in GW as opposed to ZAR 103,030 in GW + ICU. DALYs were 1.48 and 1.10 in GW versus GW + ICU, respectively. The ratio of difference in costs and health outcomes between the two management strategies produced an ICER of ZAR 73,091 per DALY averted, a value above the cost-effectiveness threshold of ZAR 38,465.

conclusionsResults indicated that purchasing ICU capacity from the private sector during COVID-19 surges may not be a cost-effective investment. The 'real time', rapid, pragmatic, and transparent nature of this analysis demonstrates an approach for evidence generation for decision making relating to the COVID-19 pandemic response and South Africa's wider priority setting agenda.

Indexed as

Cost-Benefit AnalysisCOVID-19Critical CareHumansPatients' RoomsQuality-Adjusted Life YearsSARS-CoV-2South AfricaCost‐effectivenessCOVID-19Intensive care unitPriority settingSARS-CoV-2South Africa

Identifiers

PMID33482807
PMCPMC7820836
OpenAlexW3125813364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.